The Detection Of Bile Tumor Markers (CA199, AFP, CEA) In Clinical Significance Of Diagnosed Cholangiocarcinoma

[Objective]:This experiment focuses on cholangiocarcinoma patients with bile tumor markers (CA199, AFP, CEA) test for the diagnosis of cholangiocarcinoma clinical significance.[Method]:Patients with admission by B ultrasound, CT, MRI+MRCP affect the technical inspection, from March2012to March2013, the Second Affiliated Hospital of Kunming Medical University Hepatobiliary Surgery and Gastroenterology hospitalized patients with bile duct diseases initially divided intosuspicious patients with bile duct cancer and benign bile duct lesions, these patients in the preoperative fasting blood to check serum tumor markers in serum samples and specimens, treatment after surgery, ERCP, PTCD surgery and surgery using a syringe to extract bile specimensspecimens the ERCP, part of the bile PTCD surgery and surgical specimens sent, all serum and bile samples immediately after removal into the low temperature of-20℃refrigerator tosave.Bile cytology examination and postoperative pathological examination results through the development of strict inclusion and exclusion criteria will comply with the standards of the patients were divided into patients with bile duct cancer and benign bile duct lesions group, the experimental group and the control group. Including29cases of cholangiocarcinoma patients,12men (41%) and17females (59%), the sex ratio:0.7/1, between41to79years of age, the average age is64years old; benign bile duct lesions of patients in28cases,15males and13females, the sex ratio is1/1.2, between the ages of26to87years, the average age of57years old. Bile and serum samples of patients with cholangiocarcinoma and bile duct benign lesions using radioimmunoassay, and electrochemiluminescence detection, two sets of detection of serum bile tumor markers the resulting values were used for statistical analysis statistical methods, come to the conclusion of the experiment.[Results]:1.1Serum CA199in cholangiocarcinoma group (116.4±72.6) U/ml, in benign bile duct lesion group (19.4±13.6) U/ml (P<0.01), that we can draw a conclusion that serum CA199higher than the benign lesions of the bile duct.1.2Bile CA199in cholangiocarcinoma group (294.7±135.9) U/ml, bile duct benign group (36.9±14.6) U/ml (P<0.01), we can draw a conclusion that cholangiocarcinoma group bile CA199higher than the benign lesions of the bile duct.1.3Bile CA199in Cholangiocarcinoma (294.7±135.9) U/ml, serum CA199in cholangiocarcinoma (116.4±72.6) U/ml (P<0.01), we can draw a conclusion that cholangiocarcinoma bile CA199values higher than serum CA199.2.1Serum CEA in cholangiocarcinoma group (16.3±4.7) U/ml, bile duct benign group (3.2±1.7) U/ml (P<0.05), we can draw a conclusion that serum CEA in cholangiocarcinoma group higher than benign lesions of the bile duct.2.2Bile CEA in cholangiocarcinoma group (32.7±11.5) U/ml, bile duct benign group (3.9±2.6) U/ml (P<0.05), we can draw a conclusion that the cholangiocarcinoma group of bile CEA higher than benign lesions of the bile duct.2.3Bile CEA in Cholangiocarcinoma group (32.7±11.5) U/ml, serum CEA in cholangiocarcinoma group (16.3±4.7) U/ml (P<0.05), we can draw a conclusion that cholangiocarcinoma bile CEA values higher than the of cholangiocarcinoma serum CEA.3.1serum AFP in cholangiocarcinoma group (14.1±9.6) U/ml, benign bile duct lesion group (7.4±3.6) U/ml (P>0.05), the difference was not statistically significant, the the cholangiocarcinoma group with benign bile duct lesions serum AFPThe value of the difference was not significant.3.2bile AFP in cholangiocarcinoma group (21.7±11.3) U/ml, bile duct benign group (9.5±4.9) U/ml (P>0.05), the difference was not statistically significant, the cholangiocarcinoma group and bile duct the benign lesions bile AFP The value of the difference was not significant. 3.3cholangiocarcinoma bile AFP (21.7±11.3) U/ml, cholangiocarcinoma serum AFP (14.1±9.6) U/ml (P>0.05), the difference was not statistically significant, the cholangiocarcinoma group bile AFP benign bile duct lesions no significant difference of serum AFP value.(Conclusion]:(1) Serum of patients with cholangiocarcinoma or bile tumor markers CEA, CA199can be used as effective indicators of the diagnosis of cholangiocarcinoma.(2) Through determination of patients with the bile tumor marker CEA, CA199, its role in the diagnosis of cholangiocarcinoma is superior to serum tumor markers CEA, CA199determination.(3) Combined detection of bile tumor marker CA199+CEA can increase the rate of diagnosis cholangiocarcinoma disease.(4) Tumor markers AFP help to improve the differential diagnosis of bile duct cancer and liver cancer.